In our study, CAZ-AVI + ATM and DCT present comparable effectiveness with appropriate therapy for the treatment of patients presenting with BSI caused by K. pneumoniae strains resistant to all available BL/BLIs including the newer CAZ-AVI, meropenem−vaborbactam and imipenem−cilastatin−relebactam. This evidence concerns the gene ATM and bathing suit ichthyosis.